Glenmede Trust’s Imperva, Inc. IMPV Stock Holding History

Glenmede Trust’s Portfolio IMPV Stock Details IMPV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,880	Closed	-$477K	–	1975
2018 Q2	$477K	Buy	+9,880	New	+$473K	﹤0.01%	838
2015 Q2	–	Sell	-8,880	Closed	-$379K	–	2826
2015 Q1	$379K	Hold	8,880	–	–	﹤0.01%	1070
2014 Q4	$438K	Hold	8,880	–	–	﹤0.01%	1009
2014 Q3	$255K	Hold	8,880	–	–	﹤0.01%	1104
2014 Q2	$232K	Buy	8,880 +554	+7%	+$14.3K	﹤0.01%	1120
2014 Q1	$463K	Hold	8,326	–	–	﹤0.01%	889
2013 Q4	$400K	Buy	+8,326	New	+$350K	﹤0.01%	920

Other funds holding IMPV

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's IMPV Position: Q3 2018 in Review

Glenmede Trust sold out of Imperva, Inc. (IMPV) in Q3 2018, closing a stake of 9,880 shares — an estimated $477K sold.

Glenmede Trust first reported a position in IMPV in Q4 2013 and held it in 7 quarters. The position peaked at $477K in Q2 2018. 168 funds tracked by Wall St. Rank hold IMPV as of Q3 2018.

Glenmede Trust reported no remaining Imperva, Inc. position as of Q3 2018 after selling out during the quarter.
Glenmede Trust sold 9,880 Imperva, Inc. shares in Q3 2018, an estimated $477K.
Glenmede Trust first reported a position in Imperva, Inc. in Q4 2013 and held it in 7 quarters.
Glenmede Trust's Imperva, Inc. position peaked at $477K in Q2 2018.
168 funds tracked by Wall St. Rank held Imperva, Inc. as of Q3 2018.

Based on Glenmede Trust's 13F filing for Q3 2018, filed 15 Nov 2018.